HUE052886T2 - Módszerek kolesztázisos és fibrotikus betegségek kezelésére - Google Patents

Módszerek kolesztázisos és fibrotikus betegségek kezelésére

Info

Publication number
HUE052886T2
HUE052886T2 HUE17710285A HUE17710285A HUE052886T2 HU E052886 T2 HUE052886 T2 HU E052886T2 HU E17710285 A HUE17710285 A HU E17710285A HU E17710285 A HUE17710285 A HU E17710285A HU E052886 T2 HUE052886 T2 HU E052886T2
Authority
HU
Hungary
Prior art keywords
cholestatic
treatment
methods
fibrotic diseases
fibrotic
Prior art date
Application number
HUE17710285A
Other languages
English (en)
Hungarian (hu)
Inventor
Raphaël Darteil
Robert Walczak
Carole Belanger
Emilie Negro
Pierre Daubersies
Philippe Delataille
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of HUE052886T2 publication Critical patent/HUE052886T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
HUE17710285A 2016-04-11 2017-03-13 Módszerek kolesztázisos és fibrotikus betegségek kezelésére HUE052886T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305425 2016-04-11

Publications (1)

Publication Number Publication Date
HUE052886T2 true HUE052886T2 (hu) 2021-05-28

Family

ID=55755536

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17710285A HUE052886T2 (hu) 2016-04-11 2017-03-13 Módszerek kolesztázisos és fibrotikus betegségek kezelésére
HUE20194458A HUE060671T2 (hu) 2016-04-11 2017-03-13 Eljárás fibrotikus betegségek kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE20194458A HUE060671T2 (hu) 2016-04-11 2017-03-13 Eljárás fibrotikus betegségek kezelésére

Country Status (23)

Country Link
US (7) US20170290812A1 (https=)
EP (3) EP3777854B1 (https=)
JP (1) JP6894923B2 (https=)
KR (1) KR102431257B1 (https=)
CN (1) CN109069648B (https=)
AU (1) AU2017249602B2 (https=)
DK (2) DK3442580T3 (https=)
EA (2) EA202191466A1 (https=)
ES (3) ES2928408T3 (https=)
HR (1) HRP20201954T1 (https=)
HU (2) HUE052886T2 (https=)
IL (1) IL262052B (https=)
LT (1) LT3442580T (https=)
MD (1) MD3442580T2 (https=)
MX (1) MX384261B (https=)
MY (1) MY195437A (https=)
PH (1) PH12018502142B1 (https=)
PL (1) PL3442580T3 (https=)
PT (2) PT3777855T (https=)
SG (2) SG11201808402RA (https=)
SI (1) SI3442580T1 (https=)
WO (1) WO2017178172A1 (https=)
ZA (1) ZA201807389B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191466A1 (ru) 2016-04-11 2021-12-31 Женфит Способы лечения холестатических и фибротических заболеваний
WO2017178174A1 (en) * 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
KR20190122806A (ko) * 2017-03-13 2019-10-30 장피트 조합 치료요법용 약학 조성물
US11147779B2 (en) * 2017-03-21 2021-10-19 Supreet K. Deshpande Therapeutic agent for phosphodiesterase inhibition and its related disorders
JP7365054B2 (ja) * 2017-11-17 2023-10-19 ケスター，ヒューバート リンパ管平滑筋腫症及びその他の疾患に使用するための［２－［（５－ニトロ－１，３－チアゾール－２－イル）カルバモイル］フェニル］エタノエート
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
CN113677336B (zh) 2019-04-10 2024-04-30 基恩菲特公司 包含式(i)化合物和glp-1受体激动剂的组合疗法
CA3130518A1 (en) * 2019-04-12 2020-10-15 Nicolas STANKOVIC-VALENTIN Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
CA3153784A1 (en) 2019-10-28 2021-05-06 Nicolas STANKOVIC-VALENTIN Combination therapy of elafibranor and nitazoxanide having antioxident properties
CN113398125B (zh) 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
CN116507343A (zh) * 2020-11-17 2023-07-28 基恩菲特公司 治疗肝衰竭的方法
CA3196479A1 (en) * 2020-11-17 2022-05-27 Philippe Delataille Methods of treatment of liver failure
CN115197164B (zh) * 2021-04-12 2025-04-01 杜心赟 新型噻唑类化合物及其制备方法和用途
CN117241795A (zh) * 2021-05-11 2023-12-15 基恩菲特公司 治疗脓毒症的硝唑尼特
CN116077502B (zh) * 2021-11-05 2025-12-23 广州医科大学附属妇女儿童医疗中心 叶酸在预防、诊断和治疗胆道闭锁中的应用
WO2024074515A1 (en) * 2022-10-04 2024-04-11 Genfit Nitazoxanide for the treatment of hepatic impairment
CN116911513B (zh) * 2023-02-07 2024-07-26 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用
WO2025063816A1 (ko) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 티아졸 유도체 화합물을 포함하는 자궁 섬유화증 치료용 조성물
CN117838690B (zh) * 2023-10-09 2024-09-13 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20100056505A1 (en) 2005-11-21 2010-03-04 Biogen Idec Ma Inc. Substituted Pyrazalones
AP2907A (en) * 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
CA2639910A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
GB0619500D0 (en) 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
EP2178852B9 (en) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
KR101045572B1 (ko) 2007-08-14 2011-07-01 주식회사 엘지화학 Ｃｌｏｓｔｒｉｄｉｕｍ ｐｒｏｐｉｏｎｉｃｕｍ 유래의프로피오닐―ＣｏＡ 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
EP2203168B1 (en) 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
PE20121118A1 (es) 2009-05-12 2012-09-05 Romark Lab Lc Compuestos de haloalquil heteroaril benzamida
AP2012006064A0 (en) 2009-06-26 2012-02-29 Romark Lab Lc Compounds and methods for treating influenza.
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
AU2010319999B2 (en) 2009-11-16 2014-01-16 University Of Georgia Research Foundation, Inc. 2'-Fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
CN103269593A (zh) 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
KR20190060879A (ko) 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
CN103648282B (zh) 2011-05-16 2017-02-15 罗马克实验室有限公司 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013082469A2 (en) 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
CN107105660A (zh) 2014-11-11 2017-08-29 罗马克实验室有限公司 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
US20190070154A1 (en) 2015-06-24 2019-03-07 Duke University New methods of use for an anti-diarrhea agent
CN109152760B (zh) 2016-04-11 2022-09-23 基恩菲特公司 胆汁淤积性和纤维化疾病的治疗方法
WO2017178174A1 (en) 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
EA202191466A1 (ru) 2016-04-11 2021-12-31 Женфит Способы лечения холестатических и фибротических заболеваний

Also Published As

Publication number Publication date
US10117856B2 (en) 2018-11-06
EP3777854A1 (en) 2021-02-17
EA201892298A1 (ru) 2019-04-30
CA3019399A1 (en) 2017-10-19
NZ746668A (en) 2024-12-20
MY195437A (en) 2023-01-20
PT3442580T (pt) 2020-12-23
AU2017249602A1 (en) 2018-10-18
LT3442580T (lt) 2020-12-28
EP3442580B1 (en) 2020-09-23
SI3442580T1 (sl) 2021-01-29
ZA201807389B (en) 2020-01-29
ES2839453T3 (es) 2021-07-05
US20180092886A1 (en) 2018-04-05
US20190000813A1 (en) 2019-01-03
CN109069648B (zh) 2022-01-14
US10130612B2 (en) 2018-11-20
JP6894923B2 (ja) 2021-06-30
EP3442580A1 (en) 2019-02-20
KR20180129934A (ko) 2018-12-05
IL262052A (en) 2018-11-29
US10130613B2 (en) 2018-11-20
WO2017178172A1 (en) 2017-10-19
PH12018502142A1 (en) 2019-07-29
US20180085354A1 (en) 2018-03-29
MX2018012287A (es) 2019-02-07
BR112018069684A2 (pt) 2019-01-29
PT3777855T (pt) 2023-01-10
MD3442580T2 (ro) 2021-04-30
JP2019513761A (ja) 2019-05-30
US20180092884A1 (en) 2018-04-05
ES2935185T3 (es) 2023-03-02
PH12018502142B1 (en) 2023-08-11
HRP20201954T1 (hr) 2021-02-05
US20170290812A1 (en) 2017-10-12
AU2017249602B2 (en) 2022-06-16
US20180092885A1 (en) 2018-04-05
DK3442580T3 (da) 2020-12-21
SG10202004425XA (en) 2020-06-29
EA202191466A1 (ru) 2021-12-31
EP3777855A1 (en) 2021-02-17
EP3777855B1 (en) 2022-10-19
HUE060671T2 (hu) 2023-04-28
KR102431257B1 (ko) 2022-08-10
MX384261B (es) 2025-03-14
CN109069648A (zh) 2018-12-21
DK3777855T3 (da) 2023-01-09
US11103484B2 (en) 2021-08-31
PL3442580T3 (pl) 2021-04-06
SG11201808402RA (en) 2018-10-30
ES2928408T3 (es) 2022-11-17
IL262052B (en) 2021-12-01
US20200316031A1 (en) 2020-10-08
EP3777854B1 (en) 2022-07-20
US10117855B2 (en) 2018-11-06

Similar Documents

Publication Publication Date Title
ZA201807389B (en) Methods of treatment for cholestatic and fibrotic diseases
ZA201807084B (en) Methods of treatment of cholestatic diseases
ZA202006746B (en) Methods of treatment
IL253244A0 (en) Methods for treating retinal diseases
ZA201807390B (en) Methods of treatment for cholestatic and fibrotic diseases
HUS2500033I1 (hu) Intrahepatikus kolesztázisos betegségek kezelése
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
IL274541A (en) A method for treating diseases of the digestive tract using Tradifitant
IL249894A0 (en) Targeted medical nanoparticles and methods for their preparation and use
ZA201705877B (en) Method of treating diseases
ZA201808360B (en) Treatment of intrahepatic cholestatic diseases
IL253847A0 (en) Methods of treating diseases
GB201416832D0 (en) Methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
EP3151824A4 (en) Methods of treating neurodevelopmental diseases and disorders
HK40001765A (en) Methods of treatment for cholestatic and fibrotic diseases
GB201500555D0 (en) Method and device for the treatment of diseases
EP3193935A4 (en) Treatment of fibrotic diseases
GB201512139D0 (en) Methods of treatment
GB201801249D0 (en) Methods of treatment
GB201621398D0 (en) Treatment of emt-associated disease
GB201418640D0 (en) Agents and methods for treatment of cancer
AU2014902173A0 (en) Methods of treating neurodevelopmental diseases and disorders
GB201414023D0 (en) Treatment of autoimmune diseases